AstraZeneca

Creabilis appoints Simon Russell as chief business officer

Friday, May 4, 2012 04:43 PM

Creabilis, a European biotech specializing in the development of treatments for dermatology, inflammation and pain, has appointed Simon Russell as chief business officer.

More... »


NIH launches collaborative program to spur therapeutic development

Friday, May 4, 2012 08:02 AM

The National Institutes of Health (NIH) has unveiled a collaborative program, Discovering New Therapeutic Uses for Existing Molecules, that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients.

More... »


Axerion, AZ collaborate on biologic treatment approach for Alzheimer's

Wednesday, May 2, 2012 10:06 AM

Axerion Therapeutics, a private Connecticut-based biotech, and MedImmune, the global biologics arm of AstraZeneca, have entered into a research collaboration and sublicense arrangement to develop and commercialize a biologic approach for the treatment of Alzheimer's disease.

More... »

AstraZeneca’s CEO Brennan to retire

Friday, April 27, 2012 11:30 AM

Global biopharmaceutical company AstraZeneca has announced that CEO and board member David Brennan has decided to retire, effective June 1, 2012.

More... »

AZ to acquire Ardea for $1 billion

Monday, April 23, 2012 10:42 AM

Global biopharmaceutical company AstraZeneca has agreed to acquire Ardea Bioscience, a San Diego-based biotechnology company focused on the development of small-molecule therapeutics.

More... »

Report: Pharmaceutical market grew by 5.3% in 2011

Friday, April 20, 2012 12:29 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, found that in 2011, the global pharmaceutical market, in dollar terms, benefitted significantly from positive currency effects.

More... »

AstraZeneca and Conformetrix form collaboration

Monday, April 16, 2012 10:00 AM

Through a newly-formed research collaboration, Conformetrix, a company focused on optimizing drug discovery and design, will apply its proprietary NMR-based technology across AstraZeneca’s pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.

More... »

Amgen, AstraZeneca to develop and commercialize inflammation portfolio

Monday, April 2, 2012 04:38 PM

Amgen and AstraZeneca have agreed to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)).

More... »

AZ, BioFocus, Argenta collaborate on respiratory and inflammatory diseases

Thursday, March 15, 2012 06:02 AM

Galapagos’ service companies, BioFocus and Argenta, have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets in respiratory and inflammatory diseases.

More... »

AstraZeneca files lawsuit against FDA regarding quetiapine

Wednesday, March 14, 2012 09:56 AM

AstraZeneca has filed a lawsuit against the FDA in district court to overturn the FDA’s denial on March 7, 2012, of citizen petitions filed by AstraZeneca with regard to Seroquel tablets and Seroquel XR extended release tablets (quetiapine fumarate).

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs